Inicio › Diabetes tipo 2 › Oklahoma
Ensayos clínicos de Diabetes tipo 2 en Oklahoma
13 estudios sobre Diabetes tipo 2 buscan participantes en Oklahoma.
Ciudades en Oklahoma
Texto oficial del estudio (inglés)
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
- Tekton Research Oklahoma City, Oklahoma City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 nov 2026 · NCT07754461EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
- Tekton Research Oklahoma City, Oklahoma City
- South Oklahoma Heart Research Group, Oklahoma City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 12 nov 2026 · NCT07064473A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 nov 2026 · NCT07351058A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
- Central States Research, Tulsa
ReclutandoFase 3
Edades de 10 a 17 · Todos los sexos · Actualizado el 5 nov 2026 · NCT07668336A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06897475A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
- Research Site, Norman
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 oct 2026 · NCT07662109A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus
- Research Site, Oklahoma City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 oct 2026 · NCT07662213A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events
- Hightower Clinical, Oklahoma City
- Medical Research International, LLC, Oklahoma City
- Ascension St. John - Jane Phillips Medical Center, Tulsa
ReclutandoSe aceptan voluntarios sanos
Edades de 55 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06112418A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 sept 2026 · NCT07743450AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications
- Lynn Institute of Norman, Norman
ReclutandoFase 3
Edades de 45 en adelante · Todos los sexos · Actualizado el 1 sept 2026 · NCT07797335A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
- University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoFase 3
Edades de 10 a 17 · Todos los sexos · Actualizado el 7 ago 2026 · NCT06739122DISCOVERY of Risk Factors for Type 2 Diabetes in Youth
- The University of Oklahoma Health Sciences Center, Oklahoma City
ReclutandoEstudio observacional
Edades de 8 a 15 · Todos los sexos · Actualizado el 7 may 2026 · NCT06525259Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
- Lynn Health Science Institute - Oklahoma City, Oklahoma City
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 mar 2026 · NCT07282743De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.